JP2007507207A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507207A5
JP2007507207A5 JP2006528190A JP2006528190A JP2007507207A5 JP 2007507207 A5 JP2007507207 A5 JP 2007507207A5 JP 2006528190 A JP2006528190 A JP 2006528190A JP 2006528190 A JP2006528190 A JP 2006528190A JP 2007507207 A5 JP2007507207 A5 JP 2007507207A5
Authority
JP
Japan
Prior art keywords
vlp
protein
vaccine
recombinant
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006528190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507207A (ja
JP5451960B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/031326 external-priority patent/WO2005032586A1/en
Publication of JP2007507207A publication Critical patent/JP2007507207A/ja
Publication of JP2007507207A5 publication Critical patent/JP2007507207A5/ja
Application granted granted Critical
Publication of JP5451960B2 publication Critical patent/JP5451960B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006528190A 2003-09-29 2004-09-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現 Expired - Lifetime JP5451960B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
US60/506,812 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011045589A Division JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Publications (3)

Publication Number Publication Date
JP2007507207A JP2007507207A (ja) 2007-03-29
JP2007507207A5 true JP2007507207A5 (OSRAM) 2011-05-06
JP5451960B2 JP5451960B2 (ja) 2014-03-26

Family

ID=34421558

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006528190A Expired - Lifetime JP5451960B2 (ja) 2003-09-29 2004-09-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2011045589A Pending JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2014129350A Pending JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011045589A Pending JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2014129350A Pending JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Country Status (33)

Country Link
US (2) US7250170B2 (OSRAM)
EP (1) EP1673106B1 (OSRAM)
JP (4) JP5451960B2 (OSRAM)
KR (1) KR101165278B1 (OSRAM)
CN (1) CN1859923B (OSRAM)
AR (2) AR045804A1 (OSRAM)
AT (1) ATE435029T1 (OSRAM)
AU (1) AU2004277934B2 (OSRAM)
BE (1) BE2015C072I2 (OSRAM)
BR (1) BRPI0414845B8 (OSRAM)
CA (1) CA2539168C (OSRAM)
CY (2) CY1110525T1 (OSRAM)
DE (1) DE602004021828D1 (OSRAM)
DK (1) DK1673106T3 (OSRAM)
ES (1) ES2327530T3 (OSRAM)
FR (1) FR15C0083I2 (OSRAM)
HU (1) HUS1500063I1 (OSRAM)
IL (1) IL174458A (OSRAM)
IS (1) IS2694B (OSRAM)
LT (2) LTC1673106I2 (OSRAM)
LU (1) LU92902I2 (OSRAM)
MX (1) MXPA06003457A (OSRAM)
MY (1) MY140664A (OSRAM)
NL (1) NL300776I2 (OSRAM)
NO (3) NO339932B1 (OSRAM)
NZ (1) NZ545834A (OSRAM)
PL (1) PL1673106T3 (OSRAM)
PT (1) PT1673106E (OSRAM)
RU (1) RU2360001C2 (OSRAM)
SI (1) SI1673106T1 (OSRAM)
TW (1) TWI350853B (OSRAM)
WO (1) WO2005032586A1 (OSRAM)
ZA (1) ZA200601961B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
US7700103B2 (en) 2004-03-24 2010-04-20 Merck & Co., Inc. Optimized expression of HPV 52 L1 in yeast
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
WO2008026869A1 (en) * 2006-08-28 2008-03-06 Sungkyunkwan University Foundation For Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
WO2009076824A1 (zh) * 2007-11-23 2009-06-25 Shanghai Zerun Biotechnology Co., Ltd. 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
CN102215861B (zh) 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
CN103717741B (zh) * 2011-06-15 2016-04-13 中央大学校产学协力团 用于提高人乳头瘤病毒l1蛋白产量的方法
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
JP2017528137A (ja) * 2014-09-11 2017-09-28 カディラ ヘルスケア リミティド 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
KR20220140901A (ko) 2020-02-14 2022-10-18 머크 샤프 앤드 돔 엘엘씨 Hpv 백신
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
AR126813A1 (es) 2021-08-19 2023-11-15 Merck Sharp & Dohme Llc Nueva nanopartícula lipídica termostable y métodos de uso de la misma
WO2024254226A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO117541B1 (ro) * 1994-05-16 2002-04-30 Merck & Co Inc Procedeu pentru prepararea unui vaccin de papillomavirus uman, pentru administrare la om
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
IL131131A0 (en) 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
US6391585B1 (en) * 1997-05-27 2002-05-21 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
ES2275350T3 (es) * 1998-08-14 2007-06-01 MERCK & CO., INC. Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
ES2262333T3 (es) * 1998-08-14 2006-11-16 MERCK & CO., INC. Procedimiento para purificar particulas similares a virus de papilomavirus humano.
WO2000039151A1 (en) * 1998-12-23 2000-07-06 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU7569501A (en) 2000-07-21 2002-02-05 Glaxo Group Ltd Codon-optimized papilloma virus sequences
AU2003217413A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
NZ542246A (en) 2003-03-24 2007-12-21 Merck & Co Inc Optimized expression of HPV 31 L1 yeast

Similar Documents

Publication Publication Date Title
JP2007507207A5 (OSRAM)
US7498036B2 (en) Optimized expression of HPV 58 L1 in yeast
US7482015B2 (en) Optimized expression of HPV 45 L1 in yeast
JP4505452B2 (ja) 酵母におけるｈｐｖ３１ｌ１の最適化発現
US7744892B2 (en) Optimized expression of HPV 52 L1 in yeast
TH82139A (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์
TH72490B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์
TH64808B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv31 l1 ในยีสต์
HK1090953B (en) Optimized expression of hpv 31 l1 in yeast
TH66992B (th) การปรับแต่งการแสดงออกของ hpv58 l1 ในยีสต์ให้เหมาะสม
TH74110A (th) การปรับแต่งการแสดงออกของ hpv58 l1 ในยีสต์ให้เหมาะสม